Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lexicon Pharmaceuticals reports strong Q4 performance and eyes growth

Lexicon Pharmaceuticals showcased promising drug candidates and financial stability in Q4 2022.
While facing challenges in revenue generation and expense management, the company is strategically positioned for growth.
Opportunities lie in commercial launches, Phase 3 advancements, and potential partnerships to drive future success.
Overall, Lexicon's focus on maximizing asset value and advancing key drugs positions them for long-term success in the pharmaceutical market.

Lexicon Pharmaceuticals reports robust Q1 performance and eyes market expansion

Lexicon Pharmaceuticals showcased strong financials, promising drug candidates, and strategic confidence in market success.
Challenges lie in market penetration strategies, FDA feedback, and successful commercialization amidst competition.
Opportunities abound with upcoming sotagliflozin launch, advancing LX9211, and leveraging unique data for growth.

Lexicon Pharmaceuticals reports strong Q2 earnings and advances key treatments

Lexicon Pharmaceuticals demonstrated financial stability and strategic progress in Q2 2023, supported by strong cash reserves and key regulatory milestones.
The company's focus on patient-centric initiatives and upcoming product launches positions it for sustained growth and market success.
Challenges in market penetration and revenue realization require targeted strategies, while opportunities in market expansion and pipeline development offer avenues for growth.
Overall, Lexicon Pharmaceuticals shows promise with a solid foundation for future success, driven by innovation and market-focused strategies.

Lexicon Pharmaceuticals reports Q3 loss, highlights INPEFA progress and global expansion

Lexicon Pharmaceuticals faces challenges in market access and inventory trends while capitalizing on opportunities through geographic expansion and potential partnerships. The company's financial performance in Q3 2023 showed increased expenses but progress in prescription demand for INPEFA.

Lexicon Pharmaceuticals reports strong Q1 performance and growth opportunities

Lexicon Pharmaceuticals showcased strong performance and progress in Q1 2024, with a focus on product launches and market access.
Despite challenges in achieving full access and addressing specific patient needs, the company remains optimistic about future growth opportunities.
Positive customer feedback, ongoing pipeline advancements, and strategic market considerations position Lexicon well for future success and sales acceleration.

Lexicon Pharmaceuticals reports Q3 progress amidst financial challenges and opportunities

Lexicon Pharmaceuticals showcased progress in key development programs and strategic partnerships in Q3 2024.
Despite financial challenges, the company's operational strengths and focus on growth opportunities are notable.
Navigating uncertainties around ZYNQUISTA and competition in the market are key challenges ahead.
Overall, the company's performance, strengths, challenges, and opportunities shape its strategic outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Five upcoming scientific presentations will add to the body of evidence supporting the advancement of LX9211 into late-stage development

Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

THE WOODLANDS, Texas, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that analyses of clinical study results relating to INPEFA™ (sotagliflozin), its recently approved drug for heart failure, as well as Lexicon-supported data relating to changing patterns of heart failure diagnoses, will be highlighted in two sessions during ESC Congress 2023, taking place August 25-28, 2023, in Amsterdam, The Netherlands and online. On May 26, 2023, the U.S. Food and Drug Administration approved INPEFA, a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.

Lexicon to Present Analyses of INPEFA™ (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023

Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure

Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Carrie Siragusa - Vice President of Marketing Lonnel Coats - Chief Executive Officer Jeffrey Wade - President and Chief Financial Officer Craig Granowitz - Chief Medical Officer Conference Call Participants Carly Kenselaar - Citigroup Inc. Andrew Tsai - Jefferies Group LLC Operator Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.

Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2023 Earnings Call Transcript

Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.16 per share a year ago.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates

INPEFA TM (sotagliflozin) receives FDA approval for the treatment of heart failure

Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2023 financial results on Thursday, August 3rd, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023

Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors Ms. Sullivan brings her extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors

Lexicon Elects Diane E. Sullivan to Board of Directors

First late-stage study will be a Phase 2b dose optimization study, with extension to run in parallel with next-stage Phase 3 studies

Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development

Sidus Space

Virgin Galactic

Wipro Limited Sponsored ADR

Are you on the hunt for the next big thing? Ready to catch the wave before it crests?

Penny Stocks To Buy? 4 To Watch With Big News Now

INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes

UPDATE: Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

THE WOODLANDS, Texas, June 06, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies 2023 Global Healthcare Conference, taking place June 7-9, 2023.

Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference

Diversified Healthcare Trust

Globalstar

ImmunityBio

Penny stocks are often characterized by their high volatility. Their low price means that even small price changes can equate to significant percentage gains or losses.

4 Penny Stocks To Buy In June According To Insiders

Aggregate Gross Proceeds of $143.7 Million from Public Offering and Private Placement Aggregate Gross Proceeds of $143.7 Million from Public Offering and Private Placement

Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares

With a new heart failure drug in hand, Lexicon Pharmaceuticals decided to raise capital this week, causing its shares to fall by double digits. The company plans on using the funds to support Inpefa's commercial launch.

Why Lexicon Pharmaceuticals Stock Crashed This Week

Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa, as well as a broad label compared to rivals like AstraZeneca's Farxiga and Lilly's Jardiance. The company faces significant challenges in marketing Inpefa against established competitors and will need to invest heavily in sales and marketing efforts to gain market share. Lexicon's stock has potential for growth if the Inpefa launch is successful, and a buyout or partnership with a larger pharmaceutical company is possible, but LXRX remains a high-risk proposition for investors.

Lexicon Pharmaceuticals Secures Key FDA Approval, But Heavy Lifting Remains

THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Lexicon Announces Proposed Public Offering of Common Stock

Lexicon's (LXRX) shares rise as it receives FDA approval for Inpefa, a once-daily oral tablet to treat a broad population of heart failure patients.

Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval

The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc's drug as a broad treatment for all heart failure patients, including adults with type 2 diabetes, the company said on Friday.

U.S. FDA approves Lexicon Pharma's heart failure drug

Lexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart Failure

Lexicon's flagship medicine will go before regulators this month. There's a lot riding on getting an approval because it's running a bit low on cash.

Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?

Sotagliflozin reduced the risk of cardiovascular death and heart failure readmissions in patients hospitalized for worsening heart failure events in SOLOIST-WHF study

New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX ) Q1 2023 Results Conference Call May 2, 2023 5:00 PM ET Company Participants Carrie Siragusa - Executive Director, Corporate Strategy and Investor Relations Lonnel Coats - Chief Executive Officer Jeff Wade - President and Chief Financial Officer Dr. Craig Granowitz - Senior Vice President and Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yigal Nochomovitz - Citigroup Joseph Stringer - Needham and Company Operator Good day everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2023 Financial Results Conference Call. All participants will be in a listen-only mode.

Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Earnings Call Transcript

NDA for Sotagliflozin on Track for May 27th, 2023 PDUFA date Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 02, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2023 and provided an update on key corporate milestones. “Our NDA for sotagliflozin for the treatment of heart failure is on track for its May 27th PDUFA action date,” said Lonnel Coats, Lexicon's chief executive officer.

Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

News for Lexicon Pharmaceuticals Stock (LXRX)